CXCL1 and triple-negative breast carcinoma: We propose that in vivo studies using xenograft and syngeneic mouse models combined with CXCL1 neutralizing antibodies could provide valuable insights into the distinct roles of CXCL1 in LDHC-silenced triple negative breast cancer cells.